Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Provided By GlobeNewswire
Last update: Aug 14, 2025
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
Read more at globenewswire.comNASDAQ:NERV (10/2/2025, 8:24:03 PM)
2.1059
+0.01 (+0.28%)
Find more stocks in the Stock Screener
